Nabriva: Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up
(RTTNews) - Nabriva Therapeutics plc (NBRV) announced positive results from Phase 1 clinical trial that assessed the safety and pharmacokinetics of oral and intravenous XENLETA (lefamulin) in adult patients with cystic fibrosis.
Read full article »
Nabriva Therapeutics operates as a biopharmaceutical company, discovers and develops of antibiotics.
Read more